• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Heterologous recombinant adenovirus-based COVID-19 vaccine (Gam-COVID-Vac) is tolerable and highly efficacious

byNeel MistryandTeddy Guo
June 25, 2021
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Efficacy of the Gam-COVID-Vac (Sputnik V) vaccine against COVID-19 was 91.6%.

2. In the vaccine group, there were no confirmed cases of moderate or severe COVID-19 21 days after the first dose.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Global efforts to develop safe and effective vaccines for COVID-19 prevention are ongoing. In Russia, a combined vector vaccine was developed based on replication-deficient adenovirus type 26 (rAd26) and type 5 (rAd5) to trigger a durable and long-lasting immune response. During phase 1/2  clinical trials, this vaccine was well tolerated and highly immunogenic in healthy participants, allowing it to be provisionally approved for use in high-risk populations. This study aimed to evaluate phase 3 efficacy and safety results of Gam-COVID-Vac (Sputnik V) in adults, with subanalysis of adults older than 60 years. Primary endpoint was the proportion of participants with PCR-confirmed COVID-19 at 21 days after the first dose, while secondary endpoints included severity of COVID-19, changes in SARS-CoV-2 antibody levels, and incidence and severity of adverse events. According to study results, fewer patients in the vaccine group were confirmed to have COVID-19 compared to control. There were no confirmed cases of moderate or severe COVID-19 in the vaccine group 21 days after receiving the first dose. The proportion of patients with serious adverse events was similar in both groups, although none were due to vaccination. A major weakness of this study was that patients were asked to self-report symptoms of COVID-19, which was confirmed by PCR testing. It is likely that asymptomatic causes of COVID-19 were excluded from the analysis. Nevertheless, this study sheds light onto the high efficacy, immunogenicity, and tolerability profile of Gam-COVID-Vac in Russia.

Click to read the study in The Lancet

Relevant Reading: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

In-depth [randomized controlled trial]: Between Sept 7 and Nov 24, 2020, 21 977 patients were enrolled across 25 hospitals and polyclinics in Moscow, Russia. Included patients were those aged 18 and older, with negative SARS-CoV-2 PCR and IgG and IgM tests, no infectious diseases in the last 14 days, and no vaccinations 30 days before enrolment. Those that did not meet the eligibility criteria or missed the second dose were excluded. Altogether, 19 866 patients (14 964 in the vaccine group and 4902 in the placebo group) were included in analysis. Among enrolled patients, the mean age was 45.3 years (standard deviation [SD] 12.0) in the vaccine group and 45.3 years (SD 11.9) in the placebo group.

RELATED REPORTS

Intranasal vaccine against Bordetella pertussis invokes seronegative IgA response

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

Different variants presenting with different presentations amongst children with COVID-19 infections

The primary endpoint concerning PCR-confirmed COVID-19 21 days after the first vaccine dose was substantially greater in the placebo group (62 of 4902, 1.3%) than in the vaccine group (16 of 14 964, 0.1%). Overall efficacy of Gam-COVID-Vac was 91.6% (95% confidence interval [CI] 85.6-95.2), while observed efficacy was > 87% in all age and sex subgroups. From 15 to 21 days since the first dose, vaccine efficacy was 73.6% (p=0.048) which increased to 100% (p<0.0001) from day 21 and onwards. In the vaccine group, most of the COVID-19 cases occurred prior to administration of the second dose. There were zero (vaccine group) and twenty (placebo) confirmed cases of moderate or severe COVID-19 at least 21 days after the first dose. The majority of adverse events were grade 1 (7485 of 7966 events, 94%). The likelihood of serious adverse outcomes was similar in both groups (0.3% in the vaccine group vs. 0.4% in the placebo group); however, none were associated with vaccination. In total, four deaths were reported during the study (three in the vaccine group and one in the placebo group). Again, none of these deaths were vaccine related. Findings from this study suggest that Gam-COVID-Vac seems promising based on phase 3 trials and appears to be well tolerated in a large cohort.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adenovirus vectorCoronaviruscovidCOVID-19 antibodiesCOVID-19 VaccineGam-COVID-VacrAd26rAd5SARS-CoV-2Sputnik Vvaccine
Previous Post

#VisualAbstract: Aromatase inhibitors superior to tamoxifen for progression-free survival in HR⁺ advanced breast cancer

Next Post

#VisualAbstract: Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%

RelatedReports

Algorithm improves pediatric chronic cough outcomes
Infectious Disease

Intranasal vaccine against Bordetella pertussis invokes seronegative IgA response

March 22, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Emergency

Different variants presenting with different presentations amongst children with COVID-19 infections

March 13, 2023
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Weekly Rewinds

2 Minute Medicine Rewind March 6, 2023

March 8, 2023
Next Post
#VisualAbstract: Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%

#VisualAbstract: Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%

#VisualAbstract: Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%

#VisualAbstract: Higher SARS-CoV-2 infection rate in pregnant patients

Being overweight and obese associated with increased incidence of chronic kidney disease

Everolimus treatment effective for improving renal function in lung transplant patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Active surveillance strategies to improve rates of inferior vena cava filter retrieval
  • Intranasal vaccine against Bordetella pertussis invokes seronegative IgA response
  • Hydrochlorothiazide does not impact risk of kidney-stone recurrence
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options